Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
It isn’t often a sector unquestioningly excels in internal practices, but Tom O’Byrne, chief executive of Great Place to Work UK, considers, in an Expert View piece, its recent insights on how the pharmaceutical and biotech sector is achieving this and leading the way in employee engagement. 11 August 2017
As the recent G20 Summit kicked off, in the midst of unprecedented civil unrest, advocates and lobbyists of every stripe descended on Hamburg in an effort to push their agenda. 10 August 2017
UK and USA-based clinical-stage biotech Orchard Therapeutics today announces the appointment of Mark Rothera as president and chief executive. 10 August 2017
A new leading drugmaker is to be established in Russia as a result of the recently announced merging of the pharmaceutical assets of Russian state corporation Rostec and local pharmaceutical producer Marathon Group. 9 August 2017
Yungjoon Kwon, Korean patent/trademark attorney and managing director at law firm Kwon & Kim, introduces general practice and case laws related to medical use claim in South Korea in an Expert View piece. 8 August 2017
In March 2016, Barack Obama became the first US President to visit Cuba since 1928, marking one of the final stages in a progressive thaw in relations that, it was hoped, would usher in a new era of trade and cooperation between the two countries. 7 August 2017
It seemed inevitable that change was on the horizon when Emma Walmsley’s appointment as chief executive of UK pharma major GlaxoSmithKline, taking over from Sir Andrew Witty, was announced nearly a year ago. 7 August 2017
The Indian government is looking to review the existing drug price control measures in order to make medicines more affordable in the country, and at increasing the number of clinical trials taking place in the country, reports The Pharma Letter’s India correspondent. 5 August 2017
US clinical-stage biotech firm Pfenex today announced the appointment of Evert (Eef) Schimmelpennink as chief executive, president, and secretary effective August 3, 2017. 3 August 2017
Foundation Medicine, a US company specializing in genomic analysis diagnostics in oncology, looks at how advances in genomics have changed how we treat cancer, in an Expert View piece. 2 August 2017
Twenty-first century data is providing the data-heavy pharma industry with a modern dilemma: how to preserve corporate information when technological development is accelerating so fast, writes Dominic Johnstone, head of information management services at Crown Records Management. 1 August 2017
Foreign pharma companies began a major push into the Japan market in the 1950s, albeit in the form of joint ventures (JVs) since ownership above 50% was not permitted, writes long-time Japanese industry watcher P Reed Maurer, president of International Alliances Limited, in his exclusive column for The Pharma Letter. 1 August 2017
In late June this year, the US Food and Drug Administration’s Commissioner Scott Gottlieb, issued a statement on the Drug Quality and Security Act (DQSA). The FDA’s commitment to upholding and following through on moves to protect the public from poorly compounded drugs shows that the Administration means business. 1 August 2017
In an Expert View piece, Annie Sullivan, director of corporate social media at Anglo-Swedish pharma major AstraZeneca, discusses the company’s novel approach of being 'a better social media citizen' and how its adoption of this strategy at the ASCO Annual Meeting in 2017 may help evolve the role of pharma on social media. 31 July 2017
Drugs will be the subject for total labeling in the Russian pharmaceutical market according to a recent draft law, which was submitted for the consideration of the national Parliament (State Duma) by the Russian national government, reports The Pharma Letter’s local correspondent. 29 July 2017